| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Carlos A Q Santos | |
| Koh Okamoto | |||
| P2860 | cites work | Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study | Q28298477 |
| Infection in Organ Transplantation | Q30238810 | ||
| Mycobacterial infections in lung transplant recipients | Q33543141 | ||
| Impact of multidrug-resistant organisms on patients considered for lung transplantation | Q33576059 | ||
| Epidemiology and management of infections after lung transplantation | Q34271709 | ||
| Infections of the central nervous system in transplant recipients | Q34294929 | ||
| 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host | Q34390072 | ||
| Survival benefit of solid-organ transplant in the United States | Q34460109 | ||
| Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies | Q35461796 | ||
| Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients | Q35779935 | ||
| Infections after lung transplantation: time of occurrence, sites, and microbiologic etiologies | Q35834958 | ||
| Infectious complications following isolated lung transplantation | Q35956142 | ||
| New developments in the diagnosis and treatment of infections in lung transplant recipients | Q35976649 | ||
| Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. | Q36176663 | ||
| An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases | Q36727850 | ||
| Infection in solid-organ transplant recipients | Q37038203 | ||
| Methicillin-resistant Staphylococcus aureus infection after lung transplantation: 5-year review of clinical and molecular epidemiology | Q37603768 | ||
| Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality | Q37616717 | ||
| Lactobacillus probiotic use in cardiothoracic transplant recipients: a link to invasive Lactobacillus infection? | Q37805726 | ||
| Travel medicine and the solid-organ transplant recipient | Q38109984 | ||
| Three cases of donor-derived pulmonary tuberculosis in lung transplant recipients and review of 12 previously reported cases: opportunities for early diagnosis and prevention. | Q38175162 | ||
| A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. | Q38236174 | ||
| Immunization practices in solid organ transplant recipients | Q38765363 | ||
| Transplanted lungs and the "white plague": A case-report and review of the literature | Q39206615 | ||
| Staphylococcus aureus infections in the early period after lung transplantation: epidemiology, risk factors, and outcomes | Q39551380 | ||
| Analysis of pulmonary non-tuberculous mycobacterial infections after lung transplantation | Q39638382 | ||
| Perioperative Antibiotic Prophylaxis to Prevent Surgical Site Infections in Solid Organ Transplantation | Q40160357 | ||
| Efficacy and safety of short-term treatment with isoniazid and rifampicin for latent tuberculosis infection in lung transplant candidates. | Q40397994 | ||
| Tuberculosis in lung transplant recipients. | Q40514822 | ||
| Epidemiology and Outcomes of Nontuberculous Mycobacterial Infections in Solid Organ Transplant Recipients at a Midwestern Center | Q40764909 | ||
| Late respiratory infection after lung transplantation. | Q41467023 | ||
| Clostridium difficile infection, a descriptive analysis of solid organ transplant recipients at a single center | Q41546055 | ||
| Epidemiology and outcomes of deep surgical site infections following lung transplantation | Q44448738 | ||
| Tuberculosis in transplanted lungs. | Q45142152 | ||
| Clostridium difficile infection increases mortality risk in lung transplant recipients | Q45170926 | ||
| Timing of antimicrobial prophylaxis and the risk of surgical site infections: results from the Trial to Reduce Antimicrobial Prophylaxis Errors. | Q45949224 | ||
| A computer simulation model of the cost-effectiveness of routine Staphylococcus aureus screening and decolonization among lung and heart-lung transplant recipients | Q46448797 | ||
| Bacterial and fungal pneumonias after lung transplantation | Q46613211 | ||
| Pulmonary tuberculosis in lung and heart-lung transplantation: fifteen years of experience in a single center in Spain | Q46874030 | ||
| Mycobacterium abscessus infections in lung transplant recipients: 15-year experience from a single institution. | Q47650264 | ||
| Mycobacterium abscessus disease in lung transplant recipients: Diagnosis and management | Q47650898 | ||
| Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study | Q47652584 | ||
| Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa | Q47741962 | ||
| Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. | Q47748447 | ||
| Inhaled colistin following lung transplantation in colonised cystic fibrosis patients | Q47886130 | ||
| Mediastinitis in heart and lung transplantation: 15 years experience | Q47928137 | ||
| Transmission of mycobacterium tuberculosis via lung transplantation | Q47943094 | ||
| Infections in liver and lung transplant recipients: a national prospective cohort | Q48144922 | ||
| The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report-2017; Focus Theme: Allograft ischemic time | Q48608454 | ||
| Clostridium difficile infection is associated with graft loss in solid organ transplant recipients | Q49931585 | ||
| British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). | Q49955692 | ||
| Epidemiology and Outcomes of Clostridium difficile Infection in Allogeneic Hematopoietic Cell and Lung Transplant Recipients | Q50050127 | ||
| Bacteremia in lung transplant recipients in the current era. | Q51907006 | ||
| Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study. | Q54422362 | ||
| Clostridium difficile in Immunocompromised Hosts: A Review of Epidemiology, Risk Factors, Treatment, and Prevention | Q57035497 | ||
| Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study | Q57216460 | ||
| Isoniazid prophylaxis in lung transplantation | Q57219674 | ||
| Outcome ofClostridium difficile-associated disease in solid organ transplant recipients: a prospective and multicentre cohort study | Q57568952 | ||
| Tuberculosis after Solid‐Organ Transplant: Incidence, Risk Factors, and Clinical Characteristics in the RESITRA (Spanish Network of Infection in Transplantation) Cohort | Q57569151 | ||
| Post-operative Nosocomial Infections After Lung and Heart Transplantation | Q59489669 | ||
| Infection by Nocardia in Solid Organ Transplantation: Thirty Years of Experience | Q61602770 | ||
| Reactivation of tuberculosis in a donor lung after transplantation | Q67272430 | ||
| Infection in the transplanted and native lung after single lung transplantation | Q72911375 | ||
| The spectrum of mycobacterial infection after lung transplantation | Q73168479 | ||
| Pulmonary tuberculosis after lung transplantation | Q73336227 | ||
| Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients | Q73928335 | ||
| Nocardia infection in lung transplant recipients | Q77772396 | ||
| Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation | Q80611011 | ||
| Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? | Q80649264 | ||
| Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria | Q80783608 | ||
| Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome | Q80863032 | ||
| Challenges in the diagnosis and management of Nocardia infections in lung transplant recipients | Q82107548 | ||
| Incidence and management of mycobacterial infection in solid organ transplant recipients | Q83647595 | ||
| Clinical spectrum of gram-positive infections in lung transplantation | Q84360325 | ||
| Clinical practice guidelines for antimicrobial prophylaxis in surgery | Q85911799 | ||
| Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice | Q90012193 | ||
| Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice | Q90012356 | ||
| Donor derived Mycobacterium tuberculosis infection after solid-organ transplantation: A comprehensive review | Q90584771 | ||
| Colistin-based Treatment of Multidrug-resistant Gram-negative Bacterial Pulmonary Infections After Lung Transplantation | Q91129827 | ||
| Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice | Q91940674 | ||
| Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice | Q91940689 | ||
| Surgical site infections: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice | Q91940697 | ||
| Nocardia infections in solid organ transplantation: Guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation | Q92002394 | ||
| Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation | Q92002430 | ||
| Multidrug-resistant Gram-negative bacterial infections in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice | Q92129866 | ||
| Strategies for safe living following solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice | Q92190218 | ||
| Methicillin-resistant Staphylococcus aureus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice | Q92238997 | ||
| Pneumonia in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice | Q92546068 | ||
| Screening of donor and candidate prior to solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice | Q92546606 | ||
| Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines | Q92705518 | ||
| Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections | Q92963576 | ||
| P433 | issue | 6 | |
| P921 | main subject | lung transplant | Q1637912 |
| P304 | page(s) | 413 | |
| P577 | publication date | 2020-03-01 | |
| P1433 | published in | Annals of Translational Medicine | Q26842362 |
| P1476 | title | Management and prophylaxis of bacterial and mycobacterial infections among lung transplant recipients | |
| P478 | volume | 8 |
Search more.